Cancer Immunotherapy Market Size & Share, Growth Report 2032

Cancer Immunotherapy Market Size - By Product (Monoclonal Antibodies, Cancer Vaccines, Immunomodulators, Oncolytic Viral Therapies, Cytokines), Cancer Type (Lung, Breast, Colorectal, Prostate, Pancreatic), End-use & Forecast, 2024 – 2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market scope &amp; definitions

1.2&nbsp;&nbsp;&nbsp; Research design

1.2.1&nbsp;&nbsp;&nbsp; Research approach

1.2.2&nbsp;&nbsp;&nbsp; Data collection methods

1.3&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3.1&nbsp;&nbsp;&nbsp; Base year calculation

1.3.2&nbsp;&nbsp;&nbsp; Key trends for market estimation

1.4&nbsp;&nbsp;&nbsp; Forecast model

1.5&nbsp;&nbsp;&nbsp; Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp; Primary sources

1.5.2&nbsp;&nbsp;&nbsp; Data mining sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 3600 synopsis

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp;Rising prevalence of cancer

3.2.1.2&nbsp;&nbsp;&nbsp;Advancements in research and development

3.2.1.3&nbsp;&nbsp;&nbsp;Personalized medicine and biomarker development

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp;High treatment costs

3.2.2.2&nbsp;&nbsp;&nbsp;Risk of side effects associated with the treatment

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Technological landscape

3.5&nbsp;&nbsp;&nbsp; Regulatory landscape

3.6&nbsp;&nbsp;&nbsp; Porter&rsquo;s analysis

3.7&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2023

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company market share analysis

4.3&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.4&nbsp;&nbsp;&nbsp; Strategy outlook matrix

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Product, 2021 &ndash; 2032 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Monoclonal antibodies

5.3&nbsp;&nbsp;&nbsp; Cancer vaccines

5.4&nbsp;&nbsp;&nbsp; Immunomodulators

5.4.1&nbsp;&nbsp;&nbsp; Checkpoint inhibitors

5.4.2&nbsp;&nbsp;&nbsp; Immune checkpoint modulators

5.4.3&nbsp;&nbsp;&nbsp; Other immunomodulators

5.5&nbsp;&nbsp;&nbsp; Cytokines

5.6&nbsp;&nbsp;&nbsp; Oncolytic viral therapies

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Cancer Type, 2021 &ndash; 2032 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Lung cancer

6.3&nbsp;&nbsp;&nbsp; Breast cancer

6.4&nbsp;&nbsp;&nbsp; Colorectal cancer

6.5&nbsp;&nbsp;&nbsp; Melanoma

6.6&nbsp;&nbsp;&nbsp; Prostate cancer

6.7&nbsp;&nbsp;&nbsp; Pancreatic cancer

6.8&nbsp;&nbsp;&nbsp; Other cancer types

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By End-Use, 2021 &ndash; 2032 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Hospitals

7.3&nbsp;&nbsp;&nbsp; Specialty clinics

7.4&nbsp;&nbsp;&nbsp; Cancer research centers

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2021 &ndash; 2032 ($ Mn)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; North America

8.2.1&nbsp;&nbsp;&nbsp; U.S.

8.2.2&nbsp;&nbsp;&nbsp; Canada

8.3&nbsp;&nbsp;&nbsp; Europe

8.3.1&nbsp;&nbsp;&nbsp; Germany

8.3.2&nbsp;&nbsp;&nbsp; UK

8.3.3&nbsp;&nbsp;&nbsp; France

8.3.4&nbsp;&nbsp;&nbsp; Spain

8.3.5&nbsp;&nbsp;&nbsp; Italy

8.3.6&nbsp;&nbsp;&nbsp; Netherlands

8.3.7&nbsp;&nbsp;&nbsp; Rest of Europe

8.4&nbsp;&nbsp;&nbsp; Asia Pacific

8.4.1&nbsp;&nbsp;&nbsp; Japan

8.4.2&nbsp;&nbsp;&nbsp; China

8.4.3&nbsp;&nbsp;&nbsp; India

8.4.4&nbsp;&nbsp;&nbsp; Australia

8.4.5&nbsp;&nbsp;&nbsp; South Korea

8.4.6&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

8.5&nbsp;&nbsp;&nbsp; Latin America

8.5.1&nbsp;&nbsp;&nbsp; Brazil

8.5.2&nbsp;&nbsp;&nbsp; Mexico

8.5.3&nbsp;&nbsp;&nbsp; Argentina

8.5.4&nbsp;&nbsp;&nbsp; Rest of Latin America

8.6&nbsp;&nbsp;&nbsp; Middle East and Africa

8.6.1&nbsp;&nbsp;&nbsp; Saudi Arabia

8.6.2&nbsp;&nbsp;&nbsp; South Africa

8.6.3&nbsp;&nbsp;&nbsp; UAE

8.6.4&nbsp;&nbsp;&nbsp; Rest of Middle East and Africa

Chapter 9&nbsp;&nbsp;&nbsp;Company Profiles

9.1&nbsp;&nbsp;&nbsp; AbbVie Inc.

9.2&nbsp;&nbsp;&nbsp; Amgen Inc.

9.3&nbsp;&nbsp;&nbsp; AstraZeneca PLC

9.4&nbsp;&nbsp;&nbsp; Bayer AG

9.5&nbsp;&nbsp;&nbsp; Bristol-Myers Squibb Company

9.6&nbsp;&nbsp;&nbsp; Celldex Therapeutics, Inc.

9.7&nbsp;&nbsp;&nbsp; Eli Lilly and Company

9.8&nbsp;&nbsp;&nbsp; F. Hoffmann-La Roche Ltd.

9.9&nbsp;&nbsp;&nbsp; Gilead Sciences, Inc.

9.10&nbsp;&nbsp;&nbsp; GSK plc

9.11&nbsp;&nbsp;&nbsp; Immunocore Holdings plc

9.12&nbsp;&nbsp;&nbsp; Johnson &amp; Johnson

9.13&nbsp;&nbsp;&nbsp; Merck &amp; Co., Inc

9.14&nbsp;&nbsp;&nbsp; Novartis AG

9.15&nbsp;&nbsp;&nbsp; Pfizer Inc. 
&nbsp;

Cancer Immunotherapy Market

Get a free sample of this report